DMII
Drugs Made In America Acquisition II Corp. Ordinary Shares
NASDAQ: DMII · FINANCIAL SERVICES · SHELL COMPANIES
$10.03
+0.10% today
Updated 2026-06-05
Market cap
$642.10M
P/E ratio
72.00
P/S ratio
—
EPS (TTM)
$0.14
Dividend yield
—
52W range
$10 – $10
Volume
0.1M
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2024 | 2025 |
|---|---|---|
| Total assets | $138064.00 | $504.96M |
| Cash & equivalents | $17035.00 | $223.00 |
| Current assets | $59615.00 | $26037.00 |
| Total liabilities | $254783.00 | $17.80M |
| Current liabilities | $254783.00 | $300864.00 |
| Long-term debt | — | — |
| Shareholder equity | $-116719.00 | $487.16M |
| Retained earnings | $-151719.00 | $-17.78M |
| Accounts receivable | — | — |
| Inventory | — | — |
| Goodwill | — | — |
Frequently asked questions
How much free cash flow does DMII generate?
DMII produced $-1.02M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is DMII's balance sheet healthy?
DMII holds $223.00 in cash and equivalents against — in long-term debt, on $487.16M of shareholder equity. That debt is best read against the cash flow the business throws off each year.